TACE治疗53例Child C级肝硬化并发小肝癌患者疗效评价

doi:10.3969/j.issn.1672-5069.2016.02.020

摘要/Abstract

摘要： 目的评价Child C级肝硬化并发小肝癌患者行经肝动脉栓塞化疗（TACE）治疗的疗效。方法回顾性分析2002年12月~2012年12月我科53例行TACE治疗的Child C级肝硬化并发小肝癌患者的临床资料。每例患者至少行2次TACE治疗,两次治疗间隔为30~40 d,以第2次TACE治疗结束时开始随访,所有病例均随访2年,于术后第1、3、6、12、24 m复查肝功能、AFP、凝血功能指标、腹部CT或MRI检查。结果术后1、3、6、12和24 m总有效率分别为100.0%、100.0%、83.0%、54.7%、41.5%,其中1 a生存率约为60.0%,2 a生存率为45.0%;在TACE术后1 m,患者肝功能较术前变化无统计学差异,凝血功能指标变化较术前也无统计学差异 [PT为（17.1±2.4） s 对（16.7±2.2） s];在TACE术后24 m,血清ALT较术前下降,与治疗前比,有统计学差异[（89.4±21.2）U/L 对（67.9±20.4）U/L,P<0.05];死亡原因主要是基础肝病所致。结论TACE治疗Child C级肝硬化并发小肝癌患者,临床有一定的疗效,能显著延缓这类患者因肝癌进展所致的死亡。

关键词: 小肝癌, 肝硬化, 经肝动脉栓塞化疗, Child分级

Abstract: Objective To evaluate the therapeutic efficacy of transcatheter arterial chemoembolization （TACE） in patients with small hepatocellular carcinoma and underlying liver cirrhosis of Child-Pugh class C. Methods Retrospective analysis of 53 patients with cirrhosis of Child-Pugh class C complicated by small hepatocellular carcinoma who had underwent TACE in our Department from December 2002 to December 2012 was conducted. Each patient received TACE for at least two times with an interval of 30 to 40 days,and was followed after the second TACE for 2 years. Liver function,serum AFP,coagulation function and abdominal CT scan or MRI scan were monitored at 1,3,6,12 and 24 months after the treatment. Results Effective rates of TACE in this series at 1,3,6,12 and 24 months after TACE were 100.0%,100.0%,83.0%,54.7%,41.5%, respectively;There was no significant differences in liver function and coagulation function between baseline and those at 1 month after TACE; However, serum ALT levels significantly declined at 24 months after the treatment [（67.9±20.4） U/L vs.（89.4±21.2） U/L,P<0.05];And the major cause of death was fundamental liver disease. Conclusion The clinical efficacy TACE in patients with liver cirrhosis of Child-Pugh class C complicated by small hepatocellular carcinoma is reliable,and TACE markedly reduces death due to exacerbation of hepatocellular carcinoma.

Key words: Small hepatocellular carcinoma, Cirrhosis, Transcatheter arterial chemoembolization, Child-Pugh classification

肖潇, 杨均, 颜綦先, 付鑫, 李宁, 魏艳玲, 周世亮, 彭安国, 张寅, 陈东风, 胡辂. TACE治疗53例Child C级肝硬化并发小肝癌患者疗效评价[J]. 实用肝脏病杂志, 2016, 19(2): 204-207.

Xiao Xiao, Yang Jun, Yan Qixian. Efficacy of TACE treatment in 53 patients with small hepatocellular carcinoma with underlying liver cirrhosis of Child-Pugh class C[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 204-207.

参考文献

[1] 中国抗癌协会肝癌专业委员会,中国抗癌协会临床肿瘤学协作专业委员会,中华医学会肝病学分会肝癌学组. 原发性肝癌规范化诊治专家共识.肿瘤,2009,29（4）: 295-304.
[2] 中华人民共和国卫生部.原发性肝癌诊疗规范（2011年版）. 临床肿瘤学杂志,2011,16（10）:929-946.
[3] Wu FS,Zhao WH,Liang TB,et al.Survival factors after resection of small hepatocellular carcinoma.Hepatobiliary Pancreat Disint,2005,4（3）:379-384.
[4] 张辉,徐新保,何晓军,等.原发性肝癌术后肝内复发:再手术还是射频消融.医学与哲学,2013,34 （8B）:25-26.
[5] 方万强,李升平,张昌卿,等.小肝癌切缘复发预防及临床处理方法的探讨.癌症,2005,24（7）:834-836.
[6] 何磊,刘斌. 小肝癌的治疗进展. 中国肿瘤外科杂志,2013,5（5）:319-321.
[7] 张松,王磊,吴晓东,等. 伽马刀联合HIFU治疗小肝癌的临床观察. 医疗论坛杂志,2014,35（9）:28-30.
[8] 李俊.小肝癌的诊断与治疗体会.中国医学工程,2014,22（10）:38-39.
[9] 杨秉辉,丛文铭,周晓军,等. 原发性肝癌规范化诊治专家共识.实用肝脏病杂志,2009,12（5）:321-328.
[10] Miyayama S,Yamashiro M,Omuda M,et al.The march of extrahepatic collaterals：Analysis of blood supply to hepatocellularcarcinoma located in the bare area of the liver after chemoembolization. Cardiovasc Intervent Radiol,2010,33（3）:513-522.
[11] Xiao EH,Guo D,Bian DJ,et al. Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells.World J Gastroenterol,2009,15（36）:4582-4586.
[12] Kubo S,Taukamoto T,Hirohashi K,et al. Appropriate surgical management of small hepatocellular carcinomas in patients infected with hepatitis C virus. World J Surg,2003,27（4）: 437-442.
[13] 易城辉,丁来贵,袁福建,等.TACE术在肝癌治疗中的作用及其疗效分析.中国实用医药,2009,4（1）:96-97.
[14] 汪盛参,曾庆乐,陈勇,等.微导管超选择插管介入治疗小肝癌的疗效.实用医学杂志,2012, 28（11）:1850-1852.
[15] 陈晓明,罗鹏飞,邵培坚,等.肝癌阶段性栓塞化疗与常规栓塞化疗的比较研究.中华放射学杂志,2000,34（4）:271-273.
[16] Tsochatzis EA,Bosch J,Burroughs AK,et al. Liver cirrhosis. Lancet,2014,383（9930）:1749-1761.
[17] Minami Y,Minami T,Chishina H,et al. Balloon-occluded transcatheter arterial chemoem-bolization for hepatocellular carcinoma:A single-center experience. Oncology,2015,89（2）:27-32.
[18] Li Q,Ao GK,Duan F,et al. Incidence and therapeutic frequency of extrahepatic collateral arteries intranscatheter arterial chemoembolization of hepatocellular carcinoma: Experience from 182 patients with survival time more than 3 years. Eur J Radiol,2015,84（12）:2555-2563.
[19] Ohki T,Sato K,Yamagami M,et al. Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan:A retrospective analysis. Clin Drug Investig,2015,35（11）:751-759.
[20] Divella R,Daniele A,Abbate I,et al. Circulating levels of PAI-1 and SERPINE1 4G/4G polymorphism are predictive of poor prognosis in HCC patients undergoing TACE. Transl Oncol,2015,8（4）:273-278.
[21] Wu H,Liu S,Zheng J,et al. Transcatheter arterial chemoembolization（TACE） for lymph node metastases in patients with hepatocellular carcinoma. J Surg Oncol,2015,112（4）:372-376.
[22] Liao J,Xiao J,Zhou Y,et al. Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma. Mol Med Rep,2015,12（4）:6065-6071.
[23] Huo YR,Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma:A systematic review and Meta-analysis. JAMA Oncol,2015,1（6）:756-765.
[24] Yao X,Yan D,Liu D,et al. Efficacy and adverse events of transcatheter arterial chemoembolization in combination with sorafenib in the treatment of unresectable hepatocellular carcinoma. Mol Clin Oncol,2015,3（4）:929-935.
[25] Shiozawa K,Watanabe M,Ikehara T,et al. Efficacy of sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Gan To Kagaku Ryoho,2015,42（8）:953-956.